10053003Development of a novel class of ion channel blockers for the treatment of autoimmune diseaseClosedCollaborative R&DInnovate UKAutoimmune diseases such as Inflammatory Bowel Disease, Type 1 Diabetes, Rheumatoid Arthritis and Psoriasis are driven by the protective immune system attacking the body itself. These conditions are often poorly treated with existing therapeutics. Autoimmune diseases are driven by a subset of T cells (part of the body's immune system) which are uniquely dependent on an ion channel called Kv1.3\. Blockade of the action of Kv1.3 therefore provides an "Achilles heel" to precisely disable this subset of autoimmunity-driving T cells while leaving the rest of the immune system intact to continue fighting infections. Creating an antibody drug to block Kv1.3 is an attractive option. Antibody drugs have ideal properties for disease intervention and over 100 different antibody drugs have been approved in the last 20 years. Making antibodies which block ion channels, however, remains a challenge despite decades of effort. Nature provides the answer in the form of "miniproteins" (knottins) which are found in venoms and which block ion channels. This includes a knottin present in the venom of a sea anemone that blocks Kv1.3\. Unlike antibodies, knottins suffer from problems such as rapid removal from the blood circulation and unwanted cross-reactivity in the body causing side-effects. By fusing a Kv1.3-blocking knottin directly into the surface of an antibody, Maxion has created a "hybrid molecule" (a "KnotBody") which combines the best of both worlds. The resulting molecule has the optimal characteristics of an antibody AND blocks Kv1.3\. Within this project Maxion will use powerful antibody engineering tools, invented by Maxion's founder Dr. John McCafferty, to improve the potency of the initial KnotBody and progress the resulting drug candidate towards clinical trial. Ultimately Maxion aim to develop a KnotBody drug which will significantly improve the quality of life of patients by preventing conditions such as Inflammatory Bowel Disease, Type 1 Diabetes and Atopic Dermatitis.